Expert Interviews

Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.

Suzetrigine (Journavx) PI Todd Bertoch, MD, identifies the sweet spot where he thinks the new NaV1.8 inhibitor will be most effective in post-surgical and other moderate-to-severe acute pain.

Mariano, a well-known researcher in regional anesthesiology and acute pain medicine, talks about the Journavx difference, including the drug's safety profile.

Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.

Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.

Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.

Todd W. Frieze, MD, concludes this series discussing differences in benign vs cancerous tumors and key final takeaways.

Todd W. Frieze, MD, highlights the various ways to accurately assess patient thyroid hormone levels and the general guidelines on patient surveillance.

Todd W. Frieze, MD, discusses various suppression therapy approaches for patients with hypothyroidism and thyroid cancer.

Alex Tessnow, MD, concludes this series with key final takeaways.

Alex Tessnow, MD, reviews treatment approaches for elderly patients with hypothyroidism.

Alex Tessnow, MD, discusses the common symptoms and red flags associated with hypothyroidism in elderly patients.

Alex Tessnow, MD, highlights the variability of hypothyroidism among elderly patients.

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.

Panelists discuss how real-world patient cases demonstrate the importance of individualizing obstructive sleep apnea treatment plans by considering factors such as disease severity, comorbidities, lifestyle, and patient preferences to optimize outcomes.

Panelists discuss how treatment options for obstructive sleep apnea include positive airway pressure therapy, oral appliances, lifestyle modifications, and surgical interventions, with the choice depending on disease severity and patient preferences.

Panelists discuss how positive airway pressure therapy is the most effective treatment for obstructive sleep apnea, with optimal outcomes dependent on proper device settings, mask fitting, and patient education to improve adherence.

Panelists discuss how early identification of Type 1 diabetes through screening programs, combined with emerging therapies like teplizumab, offers new opportunities for intervention and improved patient outcomes in at-risk populations.

Panelists discuss how patient selection for teplizumab therapy requires screening for specific autoantibodies and stages of Type 1 diabetes, followed by a standardized 14-day outpatient infusion protocol with careful monitoring for side effects.

Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.

Panelists discuss how islet autoantibody testing serves as a critical screening tool for identifying Type 1 diabetes risk, with tests detecting antibodies against insulin, GAD65, IA-2, and ZnT8 proteins being the most clinically validated markers.

Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.

Panelists discuss how teplizumab demonstrated efficacy in clinical trials by delaying type 1 diabetes onset in high-risk patients.

Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.

Panelists discuss how screening for autoantibodies can help identify individuals at risk for type 1 diabetes before symptoms develop, enabling earlier intervention and potentially delaying disease onset.

Caissa Troutman, MD, shares 3 key strategies for managing hypertension in patients with obesity in primary care.

Panelists discuss how validated questionnaires, clinical assessment tools, and overnight monitoring devices can help identify patients at risk for obstructive sleep apnea, though polysomnography remains the gold standard for definitive diagnosis.

Panelists discuss how various obstacles impede obstructive sleep apnea diagnosis, including limited access to sleep studies, lack of patient awareness, high costs, long wait times for testing, and inconsistent screening practices among health care providers.